1 Aventis Pharma. 2 Prescription drugs Aventis Pharma Vaccines Aventis Pasteur Therapeutic proteins Aventis Behring Diagnostics Dade Behring.

Slides:



Advertisements
Similar presentations
Programme: 145 sessions & social events
Advertisements

Magician or Math-a-magician?. Math Magic Math Magic – Trick #1 Pick a number… any number! (keep it a secret though) Add 1 to that number Multiply by.
UNIVERSITY OF JYVÄSKYLÄ INTERNATIONAL COOPERATION.
Knowledge Management LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
The Geography Challenge
ELSA Shop(ping) – Spring SALE! LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Knowledge Management and Transition ICM Cluj-Napoca, 24th April 2015.
16 out of 27 member states Known as euro zones 2 nd largest traded currency after the dollar The name euro was officially adopted on 16 December 1995.
ELSA Shop(ping) LXIV International Council Meeting Opatija, Croatia October 28 th - November 3 rd 2013.
Recruitment Kick-Off Meeting in Geneva. Kick-Off Meeting in Geneva: Budget and FinancesSlide Recruitment Outline 1.Who can be recruited?
Area Definition III KAM,Bratislava. The European Law Students’ Association Albania ˙ Austria ˙ Azerbaijan ˙ Belgium ˙ Bosnia and Herzegovina ˙ Bulgaria.
ELSA Law Schools ICM Cluj-Napoca, 21st April 2015.
THE EUROPEAN UNION. HISTORY 28 European states after the second world war in 1951 head office: Brussels 24 different languages Austria joined 1995.
UEMS ORL TREASURY REPORT October 2012 M. de la Mota, F. Marchal.
THE EUROPEAN UNION. EU  1993 European Union  Main Aims  All states in the EU = a single market  One currency throughout the EU = the Euro  To have.
KAM Prague 3 rd -7 th September AA Workshop Studies Abroad Projects Embrace cultural diversity!
Doing Business in Europe Bay Area CITD Seminar Series Tuesday, September 21st, 2004 Kemarra Inc. - Key Marketing Resources & Associates San Francisco USA.
ICM Bodrum 24 th October AA Workshop Legal Research Group.
STATE OF PLAY : ESF FINANCIAL EXECUTION. 2 Overall 2012 ESF Budget Execution on 20/11/2012 Programmin g period 2012 Payment appropriation s mil.€ 2012.
NextLastEurope. NextLastEurope  The region of Europe is the area on the map shaded dark purple. Europe.
ELSA as the Franchise? LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Natural gas, and oil sectors in Europe Vaidotas Levickis Fort Worth, Texas 2015.
In the Neighborhood of the Camp Kistarcsa 2012 The new member states of the European Union and possibilities for the expansion (workshop) Presented by.
EXTREME MAKEOVER Members’ Magazine LXIV International Council Meeting Opatija, Croatia October 28 th - November 3 rd 2013.
The European Union 1 THE EUROPEAN UNION Lesson 2 Where in the world is the European Union?
Map - Region 3 Europe.
© Enterprise Europe Network South West 2009 The Eurostars Programme Kenny Legg R&D Funding for the Environmental Sector – 29 June 2010 European Commission.
Description of the flag given by The Council of Europe in 1986: "Against the blue sky of the Western world, the stars represent the peoples of Europe.
Time line By: Shirley Lin. The story of European Union
E u r o g u i d a n c e A Network of National Resource and Information Centres for Guidance Established in 1992.
E u r o g u i d a n c e A Network of National Resource and Information Centres for Guidance Established in 1992.
The 19 th of June 1990 : The Schengen Implementing Convention has been signed by : - Germany - Belgium - France - Luxembourg - Netherlands Calendar.
Computer Class – Summer 20092/21/2016 3:45 AM European Countries Albania Andorra Austria Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Czech.
Geography Review On Map 1, please identify: -Spain -France -England -Russia -Ottoman empire -Persia -China -Mughal India -Songhai Empire.
The European Union. Important Events in EU History May 9, 1950 – French Leader Robert Schuman proposes the idea of working together in coal and steel.
The European Law Students’ Association Albania ˙ Austria ˙ Azerbaijan ˙ Belgium ˙ Bosnia and Herzegovina ˙ Bulgaria ˙ Croatia ˙ Cyprus ˙ Czech Republic.
EU’s Lifelong Learning Programme Erasmus Higher Education Mobility Charter and bilaterals So where can you go?
Maps of Topic 2B Multilingualism in Europe Europe A Story of Empire (a united Europe) & Language.
Table 1. Numbers and rates of TB cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:
LXVI Internationl Council Meeting Turkey 19th – 26th of October 2014 Academic Activites Workshop Monday 20th of October –
European Innovation Scoreboard European Commission Enterprise and Industry DG EPG DGs meeting, May 2008.
Table 1. Number and rate of reported confirmed syphilis cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate,
Table 1. Number and rate of Legionnaires’ disease cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based.
CONFIDENTIAL 1 EPC, European Union and unitary patent/UPC EPC: yes EEA: no EU: no (*) (*) Also means no unitary patent Albania, Macedonia, Monaco, San.
France Ireland Norway Sweden Finland Estonia Latvia Spain Portugal Belgium Netherlands Germany Switzerland Italy Czech Rep Slovakia Austria Poland Ukraine.
INTERNATIONAL BUSINESS Unit 2 Business Development GCSE Business Studies.
Best Sustainable Development Practices for Food Security UV-B radiation: A Specific Regulator of Plant Growth and Food Quality in a Changing Climate The.
EUROPEAN UNION – MAKING OFF European Economic Community
European Union Duy Trinh.
Table 1. Reported confirmed hepatitis A cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
DISTRIBUTION AUTOMATIC - GENERATION
The 1680 Family’s Reach.
Figure 1. Number of reported hantavirus infection cases, EU/EEA, 2014
Table 1. Reported, confirmed campylobacteriosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes,
Table 1. Number and rate of reported confirmed syphilis cases per 100 000 population by country and year, EU/EEA, 2010–2014 Country
Table 1. Reported confirmed brucellosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
The European Parliament – voice of the people
The European Parliament – voice of the people
Намалување на загадувањето на воздухот со електромобилност
EU: First- & Second-Generation Immigrants
Table 1. Table 1. Reported confirmed salmonellosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y.
Table 1. Reported confirmed cholera cases, EU/EEA, 2010–2014
Table 1. Reported confirmed botulism cases: number and rate per population, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:
Table 1. Reported confirmed leptospirosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N.
European Union Membership
European representation of respiratory critical care HERMES participants. European representation of respiratory critical care HERMES participants. Countries.
Table 1. Confirmed cases of trichinellosis: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N = no,
Where in the world is the European Union?
Table 1. Reported confirmed listeriosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
Prodcom Statistics in Focus
Presentation transcript:

1 Aventis Pharma

2 Prescription drugs Aventis Pharma Vaccines Aventis Pasteur Therapeutic proteins Aventis Behring Diagnostics Dade Behring

3 Key Figures 92, 500 employees – 80% in Pharma 16 Bn€ Pharma sales – 5th in top 10 Strong & growing US presence with >35% sales 19,000 member sales force 16.8% R&D expenditure; 6500 scientists & technicians worldwide 15% of R&D expenditure dedicated to alliances; about 50 major biotech collaborations; about 250 academic collaborations

4 Drug Innovation & Approval (R&D) Disease Groups supported by powerful technology platforms Gene Therapy * -CV - Metabolic Diseases, - Osteoarthritis, Thrombosis US FRANCE GERMANY JAPAN Global and US Drug Devt Ctr - Immunology platform - Respiratory diseases - RA - CNS European Drug Devt Ctr Asian Drug Devt Ctr - Oncology, - Infectious Diseases - Neurodegenerative Diseases, (Parkinson & Alzheimer), ~6500 scientists & technicians worldwide

5 Drug Innovation & Approval in France 5 km CDG Airport ESSONNE VAL DE MARNE HAUTS DE SEINE PARIS SEINE ST DENIS Romainville Vitry-Alfortville Croix de Berny Evry Paris Research Centre European Drug Devt Centre ~2800 scientists & technicians

6 New drug discovery technologies Candidate Identification Lead Identification Target Selection Preclinical Candidate Identification PhI / IIaPhIIbPhIIIRegulatory Review Functional Genomics Technologies DNA chips Proteomics, cellular & animal models.. Lead Identification Technologies MedChem, ChemBiol, Structural Genomics and Biology…. Technologies for Exploratory Development eADMET, TGX, PGX, Biomarkers…. Technologies for Global Rapid submissions e-submissions….. Integrated Data and Knowledge Management

7 Integration of Genomics Technologies & Disease Biology Platforms Genomics Technology Platforms Aventis Genomics Centers Disease Biology Platforms Metabolism Oncology CNS / ND Cardiovascular Rheumatoid Arthritis Osteoarthritis - DJD Respiratory Diseases Anti-Infectives Immunology platform External Collaborations & Networks Targets relevant to disease

8 Key Challenges The post-human genome sequence race functional genomics proteomics protein structure prediction re-thinking chemical approaches re-thinking clinical development Continuous integration of technologies (alliances and partnering), information and knowledge (knowledge networks) Availability of skilled work force (right skill-set and mind-set)

9 In partnership with the European Commission: 12 Marie Curie Industry Host Fellowships for a 2 year period. Post-doc Opportunities in Aventis Pharma, France Parkinson’s Disease Gene Targets (3 positions) Molecular Modeling and High Throughput Medicinal Chemistry (3 positions) From Protein-Protein Interactions (yeast 2H) to Lead Discovery Process (3positions) Cardiovascular Gene Therapy (1 position) Adenoviral Vector-based system for Functional Genomics (1 position) Bio-Informatics in Toxicogenomics (1 position) Immediate Starting Date

10 In partnership with the European Commission Post-doc Opportunities in Aventis Pharma, France The position are open to members of the E.C. or resident of associated countries for more than 5 years. The age limit at the time of selection is 35 years old. Austria, Belgium, Bulgaria, Czech republic, Denmark, Estonia, Finland, Germany Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Liechtenstein Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Republic of Cyprus, Romania Slovakia, Slovenia, Sweden, Spain, United Kingdom However French citizens are ineligible as well as those who have been resident in France for more than 12 out of the last 24 months.

11 Coming soon 9 post-doctoral positions Post-doc Opportunities in Aventis Pharma, France Kinases in Oncology and Neurodegenerative diseases Gene Transfer in Angiogenesis Genomic Studies for the glial-neuronal interactions Statistics for Pharmacogenetics

12 Post-doc Opportunities in Aventis Pharma, France 250 KF/year (38KEuros/year) Social security included days holiday Project Team Networking Publications/patents Confidentiality

13 Come and join us on the Aventis stand to learn more about our post-doctoral opportunities !